Elucent Medical Secures Series C Funding to Advance Oncologic Surgery Innovation
Summary
EnVisio\xae leverages proprietary technology that converts existing surgical tools to smart navigated instruments that can be tracked in real-time and guided with millimeter precision. EnVisio is currently optimized to guide the surgical treatment of breast cancer, while adoption of the technology has expanded to address other soft tissue oncology surgeries. "We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures," says Jason Pesterfield, President and CEO of Elucent Medical. We are dedicated to investing on the right side of healthcare, growing companies that enable clinicians to improve the delivery of care and the experiences and outcomes for patients. Visit www.rccapital.com for more information.Elucent Medical is a leading innovator in the field of oncologic surgical treatment solutions, dedicated to improving patient outcomes through precision and efficacy.